MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) today announced an expansion of the previously announced exclusive licensing deal with Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which used together with prostate specific antigen, PSA, can reduce the need for prostate biopsies by over 50%. OPKO exercised a right of first refusal to secure additional proprietary information, patents, know-how, property and technology associated with time-resolved fluorescence detection technology, which is directly applicable to the novel prostate cancer biomarkers. OPKO will pursue commercialization of the assay panel on platforms for use in a laboratory setting as well as the point-of-care.
